Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tirsit Ketsela Zeleke, Zegaye Agmassie Bazezew & Rahel Belete Abebe. (2023) The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia. Hepatic Medicine: Evidence and Research 15, pages 129-140.
Read now
Read now
Anne E. Schweighardt & Katherine M. Juba. (2018) A Systematic Review of the Evidence Behind Use of Reduced Doses of Acetaminophen in Chronic Liver Disease . Journal of Pain & Palliative Care Pharmacotherapy 32:4, pages 226-239.
Read now
Read now
Raúl J Andrade, Susana López-Ortega, Mª Carmen López-Vega, Mercedes Robles, Ignacio Cueto & Mª Isabel Lucena. (2008) Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Review of Clinical Pharmacology 1:2, pages 261-276.
Read now
Read now
Roger S McIntyre, Zilomi D Panjwani, Ha T Nguyen, Hanna O Woldeyohannes, Mohammad Alsuwaidan, Joanna K Soczynska, Maria T Lourenco, Jakub Z Konarski & Sidney H Kennedy. (2008) The hepatic safety profile of duloxetine: a review. Expert Opinion on Drug Metabolism & Toxicology 4:3, pages 281-285.
Read now
Read now
Raúl J Andrade, Raquel Camargo, M Isabel Lucena & Rocío González-Grande. (2004) Causality assessment in drug-induced hepatotoxicity. Expert Opinion on Drug Safety 3:4, pages 329-344.
Read now
Read now
M Isabel Lucena, Alfonso Carvajal, Raúl J Andrade & Alfonso Velasco. (2003) Antidepressant-induced hepatotoxicity. Expert Opinion on Drug Safety 2:3, pages 249-262.
Read now
Read now
Articles from other publishers (43)
Linrong Chen, Xu Zhen & Xiqun Jiang. (2022) Activatable Optical Probes for Fluorescence and Photoacoustic Imaging of Drug‐Induced Liver Injury. Advanced NanoBiomed Research 2:12.
Crossref
Crossref
Yue Wu, Wenzhong Xiao, Weida Tong, Jürgen Borlak & Minjun Chen. (2022) A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug Discovery Today 27:1, pages 337-346.
Crossref
Crossref
Swati Chouhan, Prajna Anirvan & Shivaram Prasad Singh. 2022. Pharmacotherapy for Liver Cirrhosis and Its Complications. Pharmacotherapy for Liver Cirrhosis and Its Complications
49
67
.
A.-R. Kabbani, T. L. Tergast, M. P. Manns & B. Maasoumy. (2019) Behandlungsstrategien des akut-auf-chronischen LeberversagensTreatment strategies for acute-on-chronic liver failure. Medizinische Klinik - Intensivmedizin und Notfallmedizin 116:1, pages 3-16.
Crossref
Crossref
Thomas H. Taylor, Dalia Ibrahim & James H. Lewis. 2021. Tuberculosis and Nontuberculous Mycobacterial Infections. Tuberculosis and Nontuberculous Mycobacterial Infections
372
408
.
Merrie Mosedale & Paul B. Watkins. (2020) Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. Journal of Medicinal Chemistry 63:12, pages 6436-6461.
Crossref
Crossref
Einar S. Björnsson. (2020) Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury. Clinics in Liver Disease 24:1, pages 1-10.
Crossref
Crossref
Roohi Mohi-ud-din, Reyaz Hassan Mir, Gifty Sawhney, Mohd Akbar Dar & Zulfiqar Ali Bhat. (2019) Possible Pathways of Hepatotoxicity Caused by Chemical Agents. Current Drug Metabolism 20:11, pages 867-879.
Crossref
Crossref
Arie Regev, Melissa Palmer, Mark I. Avigan, Lara Dimick-Santos, William R. Treem, John F. Marcinak, Daniel Seekins, Gopal Krishna, Frank A. Anania, James W. Freston, James H. Lewis, Arun J. Sanyal & Naga Chalasani. (2019) Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 49:6, pages 702-713.
Crossref
Crossref
N. V. Filippova, Yu. B. Barylnik & A. A. Shuldyakov. (2019) The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:4, pages 43.
Crossref
Crossref
Shefali Chopra & Romil Saxena. (2018) Drug-Induced Liver Injury—Perspectives from Pathology. Current Pharmacology Reports 4:3, pages 182-192.
Crossref
Crossref
A. Mak & J. Uetrecht. 2018. Comprehensive Toxicology. Comprehensive Toxicology
681
716
.
Paul B. Watkins & Merrie Mosedale. 2017. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
774
798
.
G. Shelton McMullan & James H. Lewis. 2017. Tuberculosis and Nontuberculous Mycobacterial Infections. Tuberculosis and Nontuberculous Mycobacterial Infections
439
482
.
G. Shelton McMullan & James H. Lewis. (2017) Tuberculosis of the Liver, Biliary Tract, and Pancreas. Microbiology Spectrum 5:1.
Crossref
Crossref
J. Steuart Richards, Sharon Dowell & Mercedes Quinones. 2017. Comorbidity in Rheumatic Diseases. Comorbidity in Rheumatic Diseases
345
380
.
M. B. Hilscher, L. J. Odell, L. J. Myhre, L. Prokop & J. Talwalkar. (2016) The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions. Journal of Clinical Pharmacy and Therapeutics 41:6, pages 587-591.
Crossref
Crossref
Naga Chalasani & Arie Regev. (2016) Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?. Gastroenterology 151:6, pages 1046-1051.
Crossref
Crossref
Suraj J Patel, Jay Luther, Stefan Bohr, Arvin Iracheta-Vellve, Matthew Li, Kevin R King, Raymond T Chung & Martin L Yarmush. (2016) A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity. Clinical and Translational Gastroenterology 7:3, pages e153.
Crossref
Crossref
Vincent Lo ReIIIIII, Dena M. Carbonari, James D. Lewis, Kimberly A. Forde, David S. Goldberg, K. Rajender Reddy, Kevin Haynes, Jason A. Roy, Daohang Sha, Amy R. Marks, Jennifer L. Schneider, Brian L. Strom & Douglas A. Corley. (2016) Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. The American Journal of Medicine 129:3, pages 283-291.e5.
Crossref
Crossref
M. James Lopez & Jacob L. Bilhartz. 2014. Diseases of the Liver in Children. Diseases of the Liver in Children
371
388
.
Alberto Corsini & Michele Bortolini. (2013) Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport. The Journal of Clinical Pharmacology 53:5, pages 463-474.
Crossref
Crossref
James H. Lewis & Jonathan G. Stine. 2013. Drug-Induced Liver Disease. Drug-Induced Liver Disease
369
401
.
Zheng Wang, Xu Liang, Jing Yu, Xiaohui Zheng, Yulin Zhu, Ying Yan, Ningning Dong, Lijun Di, Guohong Song, Xinna Zhou, Xiaoli Wang, Huabing Yang, Jun Ren & Herbert Kim Lyerly. (2012) Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients. Journal of Gastroenterology and Hepatology 27:8, pages 1348-1352.
Crossref
Crossref
Albert J. Czaja. (2011) Drug-Induced Autoimmune-Like Hepatitis. Digestive Diseases and Sciences 56:4, pages 958-976.
Crossref
Crossref
Raúl J Andrade & M Isabel Lucena. 2010. Evidence‐Based Gastroenterology and Hepatology. Evidence‐Based Gastroenterology and Hepatology
771
786
.
Naga Chalasani & Einar Björnsson. (2010) Risk Factors for Idiosyncratic Drug-Induced Liver Injury. Gastroenterology 138:7, pages 2246-2259.
Crossref
Crossref
Elena Toscano, Judit Cotta, Mercedes Robles, Ma Isabel Lucena & Raúl J. Andrade. (2010) Toxicidad hepática inducida por los nuevos fármacos inmunosupresores. Gastroenterología y Hepatología 33:1, pages 54-65.
Crossref
Crossref
N. K. GUPTA & J. H. LEWIS. (2008) Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Alimentary Pharmacology & Therapeutics 28:9, pages 1021-1041.
Crossref
Crossref
Moustafa HM El-Naggar, Ahmed Helmy, Mahmoud Moawad, Mohamed Al-Omary, Yusuf Al-Kadhi & Bassil Habib. (2008) Late-Onset Rosiglitazone-Associated Acute Liver Failure in a Patient with Hodgkin's Lymphoma. Annals of Pharmacotherapy 42:5, pages 713-718.
Crossref
Crossref
Ma Isabel Lucena, Miren García-Cortés, Raquel Cueto, JL Lopez-Duran & Raúl J Andrade. (2008) Assessment of drug-induced liver injury in clinical practice. Fundamental & Clinical Pharmacology 22:2, pages 141-158.
Crossref
Crossref
James H. Lewis, Mary Ellen Mortensen, Steven Zweig, Mary Jean Fusco, Jeffrey R. Medoff & Rene Belder. (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46:5, pages 1453-1463.
Crossref
Crossref
Wissam Bleibel, Stephen Kim, Karl D’Silva & Eric R. Lemmer. (2007) Drug-Induced Liver Injury: Review Article. Digestive Diseases and Sciences 52:10, pages 2463-2471.
Crossref
Crossref
James Lewis. 2007. Drug-Induced Liver Disease, Second Edition. Drug-Induced Liver Disease, Second Edition
439
464
.
Kevin P DeSanty & Celene M Amabile. (2016) Antidepressant-lnduced Liver Injury. Annals of Pharmacotherapy 41:7-8, pages 1201-1211.
Crossref
Crossref
James H. Lewis. (2006) ‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective. Pharmacoepidemiology and Drug Safety 15:4, pages 221-229.
Crossref
Crossref
Susan K Lazerow, Maaza S Abdi & James H Lewis. (2005) Drug-induced liver disease 2004. Current Opinion in Gastroenterology 21:3, pages 283-292.
Crossref
Crossref
Willis C Maddrey. (2005) Drug-Induced Hepatotoxicity. Journal of Clinical Gastroenterology 39:4, pages S83-S89.
Crossref
Crossref
I. Bjarnason, F. Bissoli, A. Conforti, L. Maiden, N. Moore, U. Moretti, K.D. Rainsford, K. Takeuchi & G.P. Velo. 2005. Nimesulide — Actions and Uses. Nimesulide — Actions and Uses
315
415
.
R. Gonzlez-Grande, R.J. Andrade Bellido, M.I. Lucena Gonzlez & R. Alcntara Benitez. (2004) Farmacolog?a de la hepatopat?a cr?nica. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9:8, pages 521-527.
Crossref
Crossref
Masako OKAZAKI, Yasutaka TAKINISHI, Masaaki TANAKA, Yasuhiko ASANO, Hiroshi GOMIBUCHI, Shizuma TSUCHIYA & Katsuji OGUCHI. (2004) Effects of Troglitazone on Diabetic Nephropathy and Hypercoagulation in KK and KK-A yMice Fed a High Fructose Diet. The Showa University Journal of Medical Sciences 16:2, pages 109-116.
Crossref
Crossref
David Novak & James H. Lewis. (2003) Drug-induced liver disease. Current Opinion in Gastroenterology 19:3, pages 203-215.
Crossref
Crossref
M. Isabel Lucena, Ra?l J. Andrade, Gianni Tognoni, Ram?n Hidalgo & Felipe Sanchez de la Cuesta. (2003) Drug use for non-hepatic associated conditions in patients with liver cirrhosis. European Journal of Clinical Pharmacology 59:1, pages 71-76.
Crossref
Crossref